Influenza A virus subtype H3N2 (also H3N2) is a subtype of viruses that cause influenza (flu). H3N2 viruses can infect birds and mammals. In birds, humans, and pigs, the virus has mutated into many strains. H3N2 is increasingly abundant in seasonal influenza, which kills an estimated 36,000 people in the United States each year.
The ever-changing "head" of an influenza virus protein has an unexpected Achilles heel, report scientists funded by the National Institute of Allergy and Infectious Diseases, one of the National Institutes of Health.
Michigan State University scientists have linked a common food preservative to an altered immune response that possibly hinders flu vaccines.
Results from a 10-year study suggest two strains of influenza that could mix and form a dangerous new strain of influenza spread by dogs.
Last year two critically ill heart patients were facing an uncertain future, but this Christmas Scotland’s first revolutionary ‘Heart in a Box’ transplantees are looking forward with hope.
Researchers developed a novel DNA influenza vaccine based on four micro-consensus antigenic regions selected to represent the diversity of seasonal H3N2 viruses across decades.
Genentech, a member of the Roche Group, today announced that the Phase III CAPSTONE-2 study showed treatment with baloxavir marboxil significantly reduced the time to improvement of influenza symptoms versus placebo in people at high risk of serious complications from the flu, which includes adults 65 years of age or older, or those who have conditions such as asthma, chronic lung disease, morbid obesity, or heart disease.
An early-stage clinical trial testing the safety and immune-stimulating ability of an experimental nasal influenza vaccine in healthy 9- to 17-year-old children and teens has begun enrolling participants at a Vaccine and Treatment Evaluation Unit site at Saint Louis University, St. Louis, Missouri.
According to the Centers for Disease Control and Prevention (CDC), there have been 16 weeks of non-stop flu season last year leading to 700,000 hospitalizations due to influenza as well as pneumonias that occurred as complications.
There's a hitch in the swing of a protein that delivers the flu virus. Rice University and Baylor College of Medicine researchers believe this mechanism may be a useful target to stop the virus from infecting cells.
Influenza vaccines that better target the influenza surface protein called neuraminidase (NA) could offer broad protection against various influenza virus strains and lessen the severity of illness, according to new research published in Cell.
New research on why the influenza vaccine was only modestly effective in recent years shows that immune history with the flu influences a person's response to the vaccine.
Researchers have developed a universal vaccine to combat influenza A viruses that produces long-lasting immunity in mice and protects them against the limitations of seasonal flu vaccines, according to a study led by Georgia State University.
This year's influenza outbreak is already the most widespread on record since health officials began keeping track about a dozen years ago, with millions of Americans being infected by emerging and current strains such as the dominant H3N2.
Alphabet’s venture arm called Google Ventures earlier is one of the supporters of a mega projects that is developing a vaccine for flu that is safe and effective. Vaccitech from United Kingdom is working towards development of the vaccine and Alphabet has shown its support by contributing $27.6 million in new funding. The funds would be used conduct clinical trials and try the new vaccine.
As flu season picks up steam across the country, it's important for people to be tested very early after symptoms that are compatible with influenza start, since there are effective treatments that can limit severe, life-threatening disease and curtail transmission to others.
NHS Dumfries and Galloway has reassured the public over the number of “Aussie flu” cases seen in the region, saying that the H3N2 flu strain is a standard one that has previously been commonplace in Scotland.
Lactic acid bacteria, commonly used as probiotics to improve digestive health, can offer protection against different subtypes of influenza A virus, resulting in reduced weight loss after virus infection and lower amounts of virus replication in the lungs, according to a study led by Georgia State University.
A collaborative research and development partnership between researchers at the University of Georgia and Sanofi Pasteur, the largest influenza vaccine manufacturer in the world, has resulted in the identification of a vaccine candidate that protects against multiple co-circulating strains of H3N2 influenza isolated over five seasons following testing in mouse and ferret models.
Flu season is here. The contagious respiratory illness caused by viruses that infect the nose, throat and lungs can cause mild to severe illness and at times may lead to death. People of every age -; including people in good health -; are at risk for flu.
Each year, public health officials monitor the spread of influenza to identify which flu strains need to go into that year's vaccines and where outbreaks will occur. But it can be difficult to predict how bad a particular flu season will be until people actually start getting sick.